Vertex Pharmaceuticals Inc / Ma (VRTX) · Nov 2, 2026 · Earnings

Vertex earnings beat revenue but EPS misses as costs surge

Miss — Non-GAAP diluted EPS $4.76 vs ~$4.82 consensus; revenue $3.44B vs ~$3.42B

Vertex earnings show strong revenue diversification and higher guidance, but EPS missed consensus as Crinetics integration and pipeline investment pushed costs sharply higher.

Vertex entered this quarter as a cystic-fibrosis cash generator trying to build additional commercial pillars in acute pain, cell and gene therapy, rare endocrine disease and kidney disease; the Crinetics acquisition was already announced to add endocrine medicines, while povetacicept's November 30, 2026 FDA decision was the next major renal milestone.

Revenue execution was ahead of the bar, but not dramatically so. Third-quarter revenue reached $3.44 billion, up 12% year over year, versus an available published consensus of roughly $3.42 billion. The mix is becoming more diversified: ALYFTREK revenue rose to $705.8 million from $247.0 million, while CASGEVY and JOURNAVX together contributed $157.5 million. The filing says, “Total revenue increased 12% to $3.44 billion compared to the third quarter of 2025.”

Figure	Q3 2026	Q3 2025	Consensus / prior guide
Total revenue (Financial Highlights)	$3,440.8M (+11.9%)	$3,076.4M	~$3,420M
Non-GAAP diluted EPS (Non-GAAP results)	$4.76 (-0.8%)	$4.80	~$4.82
ALYFTREK revenue (Product revenues)	$705.8M (+185.7%)	$247.0M
TRIKAFTA/KAFTRIO revenue (Product revenues)	$2,436.9M (-8.2%)	$2,653.6M
FY 2026 revenue guidance (Full Year 2026 Financial Guidance)	$13.15B-$13.25B		$13.10B-$13.20B

The earnings miss reflects the cost of building the next Vertex, not a revenue collapse. Non-GAAP EPS was $4.76 versus roughly $4.82 consensus, while non-GAAP net income was essentially flat year over year at $1.21 billion. The filing attributes that offset to higher operating expenses, the Crinetics acquisition, launch investment for JOURNAVX, and higher interest expense after borrowing. “Non-GAAP net income was $1.2billion in each of the third quarters of 2026 and 2025.”

The guidance raise is real, but modest and bought with materially higher spending. Full-year revenue guidance increased by $50 million at both ends, while combined GAAP expense guidance jumped to $7.15-$7.20 billion from $6.30-$6.45 billion and non-GAAP expense guidance rose to approximately $6.0 billion from $5.65-$5.75 billion. The company explicitly says the increase reflects Crinetics operations and integration, renal-franchise investment and the JOURNAVX launch. “Vertex today raised its full year 2026 total revenue guidance to $13.15billion to $13.25billion from $13.1billion to $13.2billion previously.”

Crinetics is now operationally real, while the payoff remains ahead. Vertex closed the approximately $10.0 billion acquisition in September, creating a rare-endocrine commercial pillar and adding PALSONIFY revenue, but the quarter also brought roughly $500 million of acquisition-related compensation and transaction costs and $4.5 billion of new term borrowing. “In September, Vertex completed its previously announced acquisition of Crinetics Pharmaceuticals for a total equity value of approximately $10.0billion, or $9.0billion net of cash, cash equivalents, and marketable securities acquired.”

The next decisive test is clinical and regulatory, not quarterly arithmetic. Povetacicept is under priority review for IgA nephropathy with a November 30, 2026 PDUFA date; approval would turn the renal strategy from an investment story into a commercial franchise. The filing states, “The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026.” 〔0〕

Bottom line: Vertex delivered a revenue beat and modestly raised its top-line outlook, but the EPS miss shows diversification is currently consuming as much earnings power as it creates. The business story is advancing, though this quarter is mixed rather than cleanly ahead of expectations.

What to watch next

Povetacicept FDA decision, November 30

Original filing on SEC EDGAR

More Vertex Pharmaceuticals Inc / Ma news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Vertex earnings beat revenue but EPS misses as costs surge

What to watch next

More Vertex Pharmaceuticals Inc / Ma news

Breaking down Wall Street's information edge.